Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

In the adjuvant setting, tumor biomarkers can provide an indication of the present of future behavior of a cancer. Multiple tests exist to measure these biomarkers, but the question among clinicians is: which test should be ordered?

In the adjuvant setting, 3 tumor biomarker tests—Prosigna, EndoPredict and Breast Cancer Index&mdash;have shown significant clinical utility, says Hayes. These multi-parameter assays measure either transcript or protein expression and have demonstrated analytic validity for prognosis in patients with ER-positive/HER2-negative, node-negative breast cancer.

View more from the St. Gallen's Breast Cancer Conference

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer